{
  "id": 202,
  "title": "NxStage",
  "data": "NxStage Medical, Inc. (/ˈnɛkˌsteɪdʒ/ NEK-stayj[2]) is an American company that develops, manufactures, and markets systems for the treatment of chronic kidney disease, acute kidney injury, and hypervolemia. It is a subsidiary of Fresenius Medical Care. System One, a portable hemodialysis system, is the company's primary product.[1] The company was founded by C. David Finch, Jr., MD[3] and Jeffrey H. Burbank in December 1998.[4] In 2003, the company launched System One in the critical care market. It received Food and Drug Administration clearance for home hemodialysis in June 2005.[5] In October 2005, the company became a public company via an initial public offering.[6] On November 2, 2005, the company received the Nixon Peabody/Smith&Nephew Medical Device Innovation Award in the Start-Up category from the Massachusetts Medical Device Industry Council (MassMEDIC).[7] In December 2014, the company received Food and Drug Administration clearance for System One to be used overnight while patients are sleeping.[8] In August 2017, the company received Food and Drug Administration clearance for System One for solo home hemodialysis, without a care partner, during waking hours.[9] In February 2019, the company was acquired by Fresenius Medical Care.[10][11]",
  "source_url": "https://en.wikipedia.org/wiki/NxStage"
}